Home › Obsessive-Compulsive Disorder › NCT06575075
Pilot Study of RR-HNK in OCD
RecruitingPhase 1/2
A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: * Ages 18-65 * Meet the criteria for OCD diagnosis * Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons * Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures. * Able to provide informed consent Exclusion Criteria: * Allergy or hypersensitivity to ketamine * Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician * Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control * Lifetime history of deep brain stimulation
About the study
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
What is being tested
- RR-HNK/Hydroxynorketamine (drug)
- Placebo (drug)
Sponsor: Carolyn Rodriguez · Participants: 45 · Started: Jan 23, 2026
Contact the study team
- Alessa Gaeta, BA · Phone: 650-723-4095
Official record on ClinicalTrials.gov — NCT06575075
Locations in the U.S.
| California | Stanford University School of Medicine, Palo Alto |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.